82
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society

      research-article
      1 , * , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 1 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 21 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 1 , 51 , 52 , 53 , 54
      European journal of heart failure
      Risk factors, Cardio-oncology, Cardiotoxicity, Heart failure, Risk prediction

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          This position statement from the Heart Failure Association of the European Society of Cardiology Cardio-Oncology Study Group in collaboration with the International Cardio-Oncology Society presents practical, easy-to-use and evidence-based risk stratification tools for oncologists, haemato-oncologists and cardiologists to use in their clinical practice to risk stratify oncology patients prior to receiving cancer therapies known to cause heart failure or other serious cardiovascular toxicities. Baseline risk stratification proformas are presented for oncology patients prior to receiving the following cancer therapies: anthracycline chemotherapy, HER2-targeted therapies such as trastuzumab, vascular endothelial growth factor inhibitors, second and third generation multi-targeted kinase inhibitors for chronic myeloid leukaemia targeting BCR-ABL, multiple myeloma therapies (proteasome inhibitors and immunomodulatory drugs), RAF and MEK inhibitors or androgen deprivation therapies. Applying these risk stratification proformas will allow clinicians to stratify cancer patients into low, medium, high and very high risk of cardiovascular complications prior to starting treatment, with the aim of improving personalised approaches to minimise the risk of cardiovascular toxicity from cancer therapies.

          Related collections

          Most cited references91

          • Record: found
          • Abstract: not found
          • Article: not found

          2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR).

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

            The HER2 gene, which encodes the growth factor receptor HER2, is amplified and HER2 is overexpressed in 25 to 30 percent of breast cancers, increasing the aggressiveness of the tumor. We evaluated the efficacy and safety of trastuzumab, a recombinant monoclonal antibody against HER2, in women with metastatic breast cancer that overexpressed HER2. We randomly assigned 234 patients to receive standard chemotherapy alone and 235 patients to receive standard chemotherapy plus trastuzumab. Patients who had not previously received adjuvant (postoperative) therapy with an anthracycline were treated with doxorubicin (or epirubicin in the case of 36 women) and cyclophosphamide alone (138 women) or with trastuzumab (143 women). Patients who had previously received adjuvant anthracycline were treated with paclitaxel alone (96 women) or paclitaxel with trastuzumab (92 women). The addition of trastuzumab to chemotherapy was associated with a longer time to disease progression (median, 7.4 vs. 4.6 months; P<0.001), a higher rate of objective response (50 percent vs. 32 percent, P<0.001), a longer duration of response (median, 9.1 vs. 6.1 months; P<0.001), a lower rate of death at 1 year (22 percent vs. 33 percent, P=0.008), longer survival (median survival, 25.1 vs. 20.3 months; P=0.01), and a 20 percent reduction in the risk of death. The most important adverse event was cardiac dysfunction of New York Heart Association class III or IV, which occurred in 27 percent of the group given an anthracycline, cyclophosphamide, and trastuzumab; 8 percent of the group given an anthracycline and cyclophosphamide alone; 13 percent of the group given paclitaxel and trastuzumab; and 1 percent of the group given paclitaxel alone. Although the cardiotoxicity was potentially severe and, in some cases, life-threatening, the symptoms generally improved with standard medical management. Trastuzumab increases the clinical benefit of first-line chemotherapy in metastatic breast cancer that overexpresses HER2.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer

              New England Journal of Medicine, 368(11), 987-998
                Bookmark

                Author and article information

                Journal
                100887595
                21509
                Eur J Heart Fail
                Eur J Heart Fail
                European journal of heart failure
                1388-9842
                1879-0844
                5 March 2021
                06 August 2020
                November 2020
                03 April 2021
                : 22
                : 11
                : 1945-1960
                Affiliations
                [1 ]Cardio-Oncology Service, Royal Brompton Hospital and Imperial College, London, UK
                [2 ]Duke Cancer Institute, Duke University, Durham, NC, USA
                [3 ]Breast Unit, Royal Marsden Hospital, Surrey, UK
                [4 ]Department of Oncology, University of Cambridge and NIHR Cambridge Biomedical Research Centre, Cambridge, UK
                [5 ]Division of Medical Oncology, Sinai Health System, Mount Sinai Hospital, Toronto, Canada
                [6 ]UMR-S 942, Paris University, Cardiology Department, Lariboisiere Hospital, AP-HP, Paris, France
                [7 ]Department of Translational Medical Sciences and Interdepartmental Center for Clinical and Translational Research (CIRCET), Federico II University, Naples, Italy
                [8 ]Cardio-Oncology Program, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
                [9 ]Cardio-Oncology Program, Brigham & Women’s Hospital, Harvard Medical School, Boston, MA, USA
                [10 ]Department of Cardiology, Medical University of Vienna, Vienna, Austria
                [11 ]Department of Clinical Oncology, Royal Marsden Hospital and Institute of Cancer Research, London, UK
                [12 ]Department of Medical Imaging and Radiation Sciences, Monash University and Department of Medicine, Melbourne University, Melbourne, Australia
                [13 ]Department of Cardiology, National University Heart Centre, Singapore, National University Health System, Singapore, Singapore
                [14 ]Division of Cardiology and Metabolism, Department of Cardiology, Charité and Berlin Institute of Health Center for Regenerative Therapies (BCRT) and DZHK (German Centre for Cardiovascular Research), partner site Berlin and Department of Cardiology, Charité Campus Benjamin Franklin, Berlin, Germany
                [15 ]Department of Cardiology and Pneumology, University of Goettingen Medical Center, Goettingen, Germany
                [16 ]German Center for Cardiovascular Research (DZHK), partner site Goettingen, Goettingen, Germany
                [17 ]Comprehensive Heart Failure Center, University Clinic Würzburg, Würzburg, Germany
                [18 ]First Department of Medicine – Cardioangiology, Charles University Prague, Medical Faculty and University Hospital Hradec Kralove, Prague, Czech Republic
                [19 ]MedStar Heart and Vascular Institute, Georgetown University, Washington, DC, USA
                [20 ]Ted Rogers Program in Cardiotoxicity Prevention and Joint Division of Medical Imaging, Peter Munk Cardiac Center, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Canada
                [21 ]University of Pennsylvania, Philadelphia, PA, USA
                [22 ]Cardio-Oncology Program, Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
                [23 ]Sechenov Medical University, Moscow, Russia
                [24 ]Department of Community Cardiology, Tel Aviv Jaffa District, Clalit Health Fund and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
                [25 ]School of Medicine and Public Health, University of Newcastle and “Cancer and the Heart” Program, Hunter New England LHD, Newcastle, Australia
                [26 ]Cardio-Oncology, Department of Cardio-Pneumology, University of São Paulo, São Paulo, Brazil
                [27 ]Santa Cardio-Oncology, Santa Casa de São Paulo and Rede Dor São Luiz, São Paulo, Brazil
                [28 ]Barts Heart Centre and University College London, London, UK
                [29 ]Department of Precision Medicine, Luigi Vanvitelli University of Campania, Naples, Italy
                [30 ]University of Cyprus Medical School, Nicosia, Cyprus
                [31 ]Cardio-Oncology Clinic, Heart Failure Unit, “Attikon” University Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece
                [32 ]Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
                [33 ]Cardiology Division, Internal Medicine Department, American University of Beirut Medical Center, Beirut, Lebanon
                [34 ]Department of Cardiology, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland
                [35 ]Cardioncology Unit, European Institute of Oncology, IRCCS, Milan, Italy
                [36 ]Stanford University School of Medicine, Stanford, CA, USA
                [37 ]Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA
                [38 ]Vanderbilt University Medical Center, Nashville, TN, USA
                [39 ]National Amyloidosis Centre, University College London, London, UK
                [40 ]Memorial Sloan Kettering Cancer Center, New York, NY, USA
                [41 ]Department of Haematology, Hammersmith Hospital, Imperial College, London, UK
                [42 ]Department of Haematological Medicine, King’s College Hospital, London, UK
                [43 ]University Heart Center, Department of Cardiology, University Hospital Zurich, Zurich, Switzerland
                [44 ]University of Warwick, Warwick, UK
                [45 ]Pharmacology, Centre of Clinical and Experimental Medicine, IRCCS San Raffaele Pisana, Rome, Italy
                [46 ]Faculty of Medicine and Serbian Academy of Sciences and Arts, University of Belgrade, Belgrade, Serbia
                [47 ]Emergency Institute for Cardiovascular Diseases ‘Prof. C.C. Iliescu’, Bucharest, Romania
                [48 ]University of Medicine Carol Davila, Bucharest, Romania
                [49 ]Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Hannover, Germany
                [50 ]Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany
                [51 ]Liverpool Centre for Cardiovascular Science, Liverpool Heart and Chest Hospital, Liverpool, UK
                [52 ]Cardiology Service, Cardio-Oncology Unit, La Paz University Hospital and IdiPAz Research Institute, Ciber CV, Madrid, Spain
                [53 ]Department of Cardiology, The Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle, UK
                [54 ]Cardio-Oncology Center of Excellence, Washington University in St Louis, St Louis, MO, USA
                Author notes
                [* ]Corresponding author. Cardio-Oncology Service, Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK. Tel: +44 20 7352 8121, a.lyon@ 123456ic.ac.uk
                Article
                NIHMS1663326
                10.1002/ejhf.1920
                8019326
                32463967
                3bf3b98b-6492-4b59-8691-10bd0793eee2

                This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

                History
                Categories
                Article

                Cardiovascular Medicine
                risk factors,cardio-oncology,cardiotoxicity,heart failure,risk prediction
                Cardiovascular Medicine
                risk factors, cardio-oncology, cardiotoxicity, heart failure, risk prediction

                Comments

                Comment on this article

                scite_

                Similar content72

                Cited by213

                Most referenced authors2,166